Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | PPM1B | O75688 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17887005 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL10165334 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL13560693 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL15057681 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL2965076 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL17816439 | 0.91 | CHRM2 (0.47) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL15590800 | 0.91 | SLC6A2 (0.46) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL596153 | 0.91 | CHRM2 (0.47) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL3944070 | 0.91 | SLC6A2 (0.46) | CHRM2CHRM4CHRM3PPM1BPTPN1 | |
| SCHEMBL4444010 | 0.91 | CHRM2 (0.47) | CHRM2CHRM4CHRM3PPM1BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-10-09 | — | — | US | disclosed |
| US-12195413-B2 | Ethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2023224894-A9 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20210300844-A1 | ETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-11059766-B2 | Ethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
| CN-107849006-B | Ethynyl derivatives | 豪夫迈·罗氏有限公司 | 2020-11-13 | — | — | CN | disclosed |
| EP-3303316-B1 | ETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-01-29 | — | — | EP | disclosed |
| US-20180086680-A1 | ETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-03-29 | — | — | US | disclosed |
| WO-2016123146-A1 | BRIDGED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123146-A1 | BRIDGED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2016-08-04 | — | — | WO | disclosed |
| EP-3050888-A1 | Compounds for the treatment of bacterial infections | Merck Sharp & Dohme Corp. (US) | 2016-08-03 | — | — | EP | disclosed |
| US-8030489-B2 | Ornithine derivative | ASTELLAS PHARMA INC. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100216803-A1 | ORNITHINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2141147-A1 | ORNITHINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-01-06 | — | — | EP | disclosed |
| US-20080064717-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086680-A1 | ETHYNYL DERIVATIVES | GRM1, GRM5, GRIN1 | CHRM2 1018/4885CHRM4 520/4885CHRM3 739/4885 |
| US-20100216803-A1 | ORNITHINE DERIVATIVE | PTGER4, OXER1, ODC1 | CHRM2 392/4885CHRM4 267/4885CHRM3 602/4885 |
| US-11059766-B2 | Ethynyl derivatives | GRM1, GRM5, GRIN1 | CHRM2 1018/4885CHRM4 520/4885CHRM3 739/4885 |
| US-20210300844-A1 | ETHYNYL DERIVATIVES | GRM1, GRIN1, GRM5 | CHRM2 1019/4885CHRM4 516/4885CHRM3 701/4885 |
| US-20080064717-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | DGAT1, DGAT2, DLAT | CHRM2 2687/4885CHRM4 3342/4885CHRM3 3437/4885 |
| US-12195413-B2 | Ethynyl derivatives | GRM1, GRIN1, GRM5 | CHRM2 1019/4885CHRM4 516/4885CHRM3 701/4885 |
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, PARK7 | CHRM2 3557/4885CHRM4 4545/4885CHRM3 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.